Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE of SEGMENT INFORMATION (Details)

v3.22.0.1
SCHEDULE of SEGMENT INFORMATION (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Oct. 31, 2021
Segment Reporting Information [Line Items]      
Net loss $ (3,879) $ (2,232)  
Total operating costs and expenses 3,880 2,746  
Less non-cash share-based compensation (2,354) (986)  
Operating costs and expenses excluding non-cash share based compensation expense 1,526 1,760  
Total Asset 35,238   $ 36,257
Cart Therapeutics [Member]      
Segment Reporting Information [Line Items]      
Net loss (1,611) (960)  
Operating costs and expenses excluding non-cash share based compensation expense 669 558  
Total Asset 15,412   15,068
Cancer Vaccines [Member]      
Segment Reporting Information [Line Items]      
Net loss (1,357) (906)  
Operating costs and expenses excluding non-cash share based compensation expense 480 538  
Total Asset 11,052   13,276
Anti Viral Therapeutics [Member]      
Segment Reporting Information [Line Items]      
Net loss (904) (481)  
Operating costs and expenses excluding non-cash share based compensation expense 372 271  
Total Asset 8,562   7,368
Other [Member]      
Segment Reporting Information [Line Items]      
Net loss (7) 115  
Operating costs and expenses excluding non-cash share based compensation expense 5 $ 393  
Total Asset $ 212   $ 545